Skip to main content

Meet the Editors


Francesco Marincola, MD, Sonata Therapeutics, USA

Back to top

Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.

Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre. 

Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.

Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational MedicineTranslational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.

Franco received his M.D. from the University of Milan and completed his residency at Stanford University.

Managing Editors

Joyce Hu, PhD, Sonata Therapeutics, USA

Back to top

Joyce Hu is Vice President, Head of Cancer Biology at Sonata Therapeutics, where she leads an effort to understand the interplay between cells and signals in the tumor microenvironment to develop network medicines in oncology. Previously, Joyce was a Director and Head of Research at the BioNTech US site in Gaithersburg, MD. There, she coordinated efforts in biomarker discovery, screening and validation, automation, sequencing, and bioinformatics in the development of personalized medicine in oncology. Before then, she developed personalized and off-the-shelf T cell-based therapeutics at Kite Pharma, Adaptive Biotechnologies, and Poseida Therapeutics.

Joyce received her Ph.D. in Biomedical Sciences with a focus on Immunology at the University of California, San Francisco, and performed her postdoctoral research at the La Jolla Institute for Immunology. Her academic training was focused on understanding the orchestration of immune responses to infection, autoimmunity, and cancer.

Kai Zhang, PhD, Amgen Inc., USA

Back to top

Dr. Kai Zhang heads the Corporate Strategy—Precision Medicine Search and Evaluation team at Amgen. His leads the team to proactively search for and evaluate precision medicine M&A, licensing and research collaboration opportunities. Dr. Zhang is as an active Editorial Board Member or Reviewer for over 30 scientific peer-reviewed journals, including serving as a reviewing Editor for Cancer Medicine and an Editorial Board Member for Molecular Biology Reports. He received his PhD in Pharmacology from the University of Kentucky and an MBA from University of California, Berkeley.

Section Editors

Richard Ablin, PhD DSc, University of Arizona, USA

Back to top

Section: Hot Topics

Dr. Richard J. Ablin is Professor, Department of Pathology, University of Arizona College of Medicine, Arizona Cancer Center and BIO5 Institute and President, Robert Benjamin Ablin Foundation for Cancer Research, founded in memory of his father, since 1979.  Dr. Ablin received his Ph.D. in Microbiology from SUNY at Buffalo in 1967, and continued his training in immunology as a USPHS Postdoctoral Fellow at the Medical School under the late renowned Distinguished Professor Ernest Witebsky. Dr. Ablin is the recipient of a D.Sc., honoris causa, from Lake Forest College, his undergraduate alma mater, and a Doctoris Honoris Causa from the “Carol Davila” University of Medicine and Pharmacy Bucharest. He was honored as recipient of the First Award for Scientific Excellence by The Haakon Ragde Foundation for Advanced Cancer Studies in recognition “for his invaluable contribution to humankind and exceptional scientific insight and valiant fight against cancer.”

Dr. Ablin discovered prostate-specific antigen (PSA) in 1970, which led to the development of the PSA test, and was a nominee for the Lasker Award in 1997. A pioneer of cryosurgery and the concept of “cryoimmunotherapy” for the treatment of cancer, he has extensive experience in cancer research, particularly the development and progression of cancer. Dr. Ablin is a member of Sigma Xi (of which he is President, the University of Arizona Chapter), Phi Beta Kappa and numerous professional societies. 

Cited in several biographical references, including American Men and Women of Science, Who’s Who of Emerging Leaders in America and Who’s Who in the World, Dr. Ablin has been an invited speaker at numerous national and international meetings; has contributed numerous articles to professional journals and texts; is co-editor of the book series Cancer Metastasis - Biology and Treatment and serves on the editorial board of several journals, and the author of the recent book: The Great Prostate Hoax: How Big Medicine Hijacked the PSA Test and Caused a Public Health Disaster.

Souhaila Al Khodor, PhD, Sidra Medical and Research Center, Qatar

Back to top

Section: Translational Metagenomics

Dr Al Khodor is the Director of Maternal and Child Health program in the research department at Sidra Medicine, Qatar, since July 2019 and an Investigator since January 2015. Dr Al Khodor received her Bachelor’s degree in Medical Lab. technology from the Faculty of Public Health at the Lebanese University in 2001. Soon after, she started her master’s degree in microbiology and Immunology at the American University of Beirut (2002-2005). Dr Al Khodor received her second master’s degree and PhD in Microbiology and Immunology from the University of Louisville, Louisville, KY, USA (2005-2008). Before joining Sidra, Dr Al Khodor worked as a postdoctoral fellow in the Signaling systems Unit, laboratory of Systems Biology, at the National Institute of Allergy and infectious Diseases (NIAID), National Institutes of Health (NIH) in Maryland, USA.

Dr Al Khodor’s laboratory in Sidra focuses on characterizing the role of the microbiome in health and disease, with a particular emphasis on maternal and child health and the integration of metagenomics with other omics aiming to identify predictive markers for various diseases and pathological conditions. Dr Al Khodor is an adjunct Assistant Professor at the College of Health & Life Science in Hamad Bin Khalifa University, and an Adjunct Assistant Professor at the Department of Biomedical Sciences, College of Health Sciences in Qatar University.

Dr Al Khodor has over 40 peer-reviewed publications. She currently serves as a Guest Associate Editor for Frontiers in Cellular and Infection Microbiology and an Associate Editor for the Journal of Translational Medicine since 2017.

Paolo A Ascierto, MD, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Italy

Back to top

Section: Combination Strategies

Professor Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics at that same institution. He is Associate Editor for Onco-Immunology of Annals of Oncology, Associate Editor of Journal of ImmunoTherapy of Cancer, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and member of the Editorial Board for ESMO Open. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 450 national and international meetings.

Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). Professor Ascierto has presided as Principal Investigator on over 150 clinical trials and he is author of more than 480 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, JAMA Oncology, and Annals of Oncology, among others. Primarily, his major research interests are the skin cancers molecular biology, the assessment of molecular markers for tumour progression in melanoma, biochemical and immunological monitoring, targeted therapies for melanoma, vaccination treatments and immunotherapy of solid tumors, and combination approaches for the cancer treatment.

Marina Boccardi, PhD, German Center for Neurodegenerative Diseases, Germany

Back to top

Section: Translational Process

Marina Boccardi is full Professor of Implementation Neuroscience at the University of Medicine – Rostock and DZNE Rostock-Greifswald, Germany. She earned her Psychology degree at the University of Padua, Italy, and her PhD at the University of Kuopio, now University of Eastern Finland. She works in the field of Alzheimer’s disease and related disorder from 1997, both on the clinical – until 2016 – and, mostly, the research aspects. From 2000 to 2019 she worked as a researcher at the IRCCS S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy, and from 2016 to 2019 at the University of Medicine in Geneva, Switzerland.

Her research interests progressively evolved to increasingly translational-methodological issues, after observing and reporting several gaps preventing current scientific developments to innovate clinical practice.

Geoffrey Broadhead, MD PhD, University of Sydney, Australia

Back to top

Section: Translational Ophthalmology

Dr Geoffrey Broadhead (MBBS, PhD, FRANZCO) is a practicing clinical ophthalmologist and medial retinal specialist, as well as a Clinical Associate Lecturer at the University of Sydney. He works both clinically and in industry, and has been involved in monitoring and designing clinical trials across multiple phases, as well as conducting clinical and translational ophthalmology research. 

His research interests are focused on the clinical aspects of age-related macular degeneration, retinal vascular disease and retinal degenerative diseases, including emerging translational aspects of diagnostics and therapeutics. He has published over 30 peer reviewed articles and completed international fellowship training in both the United States and United Kingdom.

Luigi Buonaguro, MD, National Cancer Institute Pascale, Italy

Back to top

Section: ImmunoVirology and ImmunoOncology

Dr Luigi Buonaguro is the Director of the Innovative Immunological Models at the National Cancer Institute - IRCCS “Pascale ”, Naples – Italy. He is an expert in identification and characterization of tumor antigens for preventive/therapeutic cancer vaccine development. His focus is mostly on shared tumor-associated antigens for off-the-shelf vaccines. Based on this approach, he has coordinated an European Consortium for the development and clinical evaluation in a Phase I clinical trial of the HEPAVAC therapeutic cancer vaccine for primary hepatocellular carcinoma ( In parallel, he is pioneering the homology between tumor antigens (TAAs) and virus/bacteria-derived antigens (MoAs) (molecular mimicry). In particular, he is contributing to understand the role and cross-reactive potency of the immune response elicited by MoAs as anti-tumor immunity in order to develop next-generation preventive/therapeutic cancer vaccines. According to Expertscape (, he is in 1st place in Italy, 10th in Europe and among the top 30 Scientists in the World for the item "Cancer VACCINE".

Alessandra Cesano, MD PhD, Nanostring Technologies, USA

Back to top

Section: Immunobiology and Immunotherapy

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. 

Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

Gennaro Ciliberto, PhD, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Italy

Back to top

Section: Emerging Therapeutics

Prof Gennaro Ciliberto is the Scientific Director of IRCCS Istituto Nazionale Tumori "Regina Elena”. He was previously an Associate Professor in Genetics at University of Pisa and Full Professor of Molecular Biology in University of Napoli. Between 2012-2016, he held the position of Scientific Director of IRCSS Istituto Nazionale Tumori, "G. Pascale" Napoli. 

Since 1989, Prof Ciliberto has been an elected member of the European Molecular Biology Organization (EMBO). He is the President of FISV (Italian Federation of Scientific Societies of Life Sciences) and was previously the President of SIBBM (Società Italiana di Biofisica e Biologia Molecolare) during 2013-2016. In 2009, he co-founded a biotechnology company, Takis s.r.l, a spin-off of the IRBM P. Angeletti, with the main focus on research and development of Cancer Immunotherapies.

Prof Ciliberto has co-authored more than 350 indexed publications (total I.F. > 1700; H-index =70) (Source: Scopus) and 30 between book chapters and editorials. He is experienced in Technology transfer as co-inventor of 30 international granted patents/patent applications. Prof Ciliberto is and Editorial Board Member and Reviewer of several international journals, and an Editor if textbook for graduate students.

His current scientific interests are: a) study of the mechanisms responsible for drug resistance in melanoma; b) alterations of lipid metabolism in cancer, mainly lung cancer; c) personalized therapy of cancer; d) genetic vaccines for the therapy of cancer.

Hao Fang, PhD, Fudan University, China

Back to top

Section: Disease Biomarkers

Dr Hao Fang is Professor of Clinical Anesthesiology at Fudan University in China. He obtained his Master’s degree and PhD at Fudan University. As a clinical anesthesiologist, he has worked in this area for more than twenty years. He is member of Chinese Association of Anesthesiologists and Deputy Chairman of Anesthesia and Perioperative Special Committee of China Human Health Science and Technology Promotion Association. He has 6 patents to his credit, of which 2 have been transferred. As a researcher, Dr Fang has supervised 18 graduate and PhD students. His research is focused on perioperative organ protection and intensive care of sepsis.

Lorenzo Gullazzi, PhD, Weill Cornell Medicine, USA

Back to top

Section: Cell Death and Senescence

Dr Lorenzo Galluzzi is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medicine (New York, NY, USA), and Assistant Professor of Cell and Developmental Biology with the Graduate School of Medical Sciences of the Weill Cornell Medicine (New York, NY, USA), and Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), as well as Faculty Member with various European Graduate Schools of Medicine (Padova, Ferrara, and Rome, Italy).

Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 500 scientific articles in international peer-reviewed journals. Since 2018, he has been consistently nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter), most recently in 2022 in three distinct disciplines (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity) an honor that he shared with only 31 other scientists worldwide, all disciplines confounded.

Besides serving as Section Editor for the Journal of Translational Medicine, Lorenzo Galluzzi operates as Editor in Chief for OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, he currently serves in various Editorial roles for multiple journals including: Cell Death and Disease, iScience, Pharmacological Research, Cell Communication and Signaling, Microbial Cell, Cell Stress and Aging.

Giuseppe Intini, PhD, University of Pittsburgh, USA

Back to top

Section: Translational Craniofacial and Dental Medicine

Born in Italy, Dr. Giuseppe Intini earned a degree in dentistry in 1995 from the University of L'Aquila (Italy). In 2000, he received a Master's degree in Oral Sciences from the University at Buffalo (NY), and in 2007 he received a PhD in Oral Biology and a certificate in clinical Periodontology from the University at Buffalo (NY). He is a Diplomate of the American Board of Periodontology.  

From 2007 to 2012 he was a postdoctoral fellow of Developmental Biology at the Harvard School of Dental Medicine in Boston (MA) and from 2012 to 2018 he has been an Assistant Professor of Oral Medicine, Infection, and Immunity at the Harvard School of Dental Medicine in Boston (MA).

Dr. Intini is an Associate Professor of Periodontics and Preventive Dentistry at the University of Pittsburgh School of Dental Medicine and an Associate Professor of Medicine at the University of Pittsburgh School of Medicine. He is a co-director of the Pittsburgh Center for Interdisciplinary Bone and Mineral Research (PCIBMR) and a member of the Center for Craniofacial Regeneration and of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. In addition, he is a visiting faculty at the Massachusetts General Hospital in Boston (MA) and a lecturer at the Harvard School of Dental Medicine in Boston (MA).

As a clinician, Dr. Intini has interest in periodontal regeneration and alveolar bone augmentation procedures. As a researcher, Dr. Intini oversees the research at the Intini Lab, which focuses on skeletal stem cells and bone regeneration, and on osteosarcoma cancer stem cells and their role in development of lung metastases.

Levon Khachigian, PhD DSc, University of New South Wales, Australia

Back to top

Section: Translational Ophthalmology

Dr Levon Khachigian PhD, DSc, MIP (Law) is Professor in Medicine at the University of New South Wales where he heads the Vascular Biology and Translational Research Laboratory in UNSW’s Faculty of Medicine and Health. Levon is a vascular cell and molecular biologist whose research has centred on understanding mechanisms underpinning the inducible expression of disease-causing genes in a range of vascular disorders and on devising novel therapies in programs of bench-to-bedside translational research. 

Levon’s innovative work has been recognized by numerous awards including the Commonwealth Health Minister's Award for Excellence in Health and Medical Research, the GlaxoSmithKline Australia Award for Research Excellence, the Australasian Science Prize and the Gottschalk Award from the Australian Academy of Science. He has published over 250 research articles and invited reviews.

Prof Khachigian co-edits this section with Dr Broadhead.

Ahmed Labib, MD, Hamad General Hospital, Qatar

Back to top

Section: Pain, Critical Care and Anaesthesia

Dr. Ahmed Labib, FRCA FFICM EDIC MSc (Anaesth) is a Senior Consultant ECMO, Critical Care, and Anesthesia and an Assistant Professor of Clinical Anesthesiology at WCM-Q. Ahmed is vice chair and the Clinical Lead of HMC Sepsis Program. He is also the Aeromedical Clinic Lead at HGH. Ahmed is an Intensivist at the Medical Intensive Care Unit at Hamad General Hospital. He joined HMC in December 2013. He is a Fellow of the Royal College of Anesthetists, London; the Faculty of ICM, London and holds the European Diploma in Intensive Care Medicine (EDIC). 

Dr. Labib accomplished advanced dual-specialty training in Anesthesia and Intensive Care Medicine (ICM) in the UK where he trained in a number of regional centers and university hospitals. Dr. Labib’s main interests are patient safety, sepsis and ECMO. 

Michael Liebman, PhD, Strategic Medicine Inc, USA

Back to top

Section: Computational Modelling and Epidemiology

Michael N. Liebman, Ph.D (theoretical chemistry and protein crystallography) is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. He serves on the Advisory Board for the International Park for Translational Biomedicine (Shanghai) and the Center of Biomedical and Health Research in Data Sciences, Univ Massachusetts(Lowell). 

Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was Associate Professor of Pharmacology and of Physiology/Biophysics at Mount Sinai School of Medicine. Michael is acting CSO for United Cancer Network. He serves on 14 scientific advisory boards, is an advisor in digital health and quantum computing and serves on the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS. 

Michael is Chair of the Informatics Program and also Chair of Translational Medicine and Therapeutics for the PhRMA Foundation and a member of their Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, for Clinico-Economics and Outcomes Research and Biomedicine Hub. He is a member of the IUPAC Division on Human Health’s Medicinal Chemistry subcommittee. He has served on the External Advisory Board for the INBRE (NIH) program for the state of Delaware since 2000. He serves on the HIMMS Innovation Committee and on the HIMSS SDOH Committee. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and of the Chinese Academy of Sciences. His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare. 

Seah H Lim, MD PhD, SUNY Upstate Medical University, USA

Back to top

Section: Translational Hematology

Dr Seah Lim is the Founder and Chief Executive Officer at Medicovestor, Inc and Adjunct Professor in the Division of Hematology and Oncology at SUNY Upstate Medical University. He has more than 25 years of leadership experience in both academia and industry. His extensive experience in drug development and the biotech industry includes being a Product Development Consultant for Bausch Health, Product Development Consultant for Genzyme, Product Development Consultant for Burroughs Wellcome & Company, and Pediatric Lead in the Global Program at Sanofi. He is currently also an Independent Director for Emmaus Medicals, Inc and Business and Scientific Advisor for Genie Therapeutics, Inc.   

 Dr Lim graduated from Aberdeen University, Scotland with a commendation degree in Medicine (MB ChB), and was the most distinguished male graduand of the year. He underwent his British thesis-based MD training in cytokines and cell therapy for acute leukemias at the University College Hospital, London, and PhD training in antibody engineering at Cambridge University, England and University of Cardiff, Wales. He had since been Full Professor with many leadership roles (from being Program Directors to the Chief of Division) in various universities in the United Kingdom and United States, including at Brown University and University of Pittsburgh School of Medicine. 

Throughout his career, Dr Lim has been an internationally recognized translational physician scientist. He has made numerous discoveries and holds 11 patents. He has published more than 180 manuscripts in high impact medical and scientific journals. He has attracted more than $18M of research grants, including numerous grants from the National Cancer Institute.

Cristina Maccalli, PhD, Sidra Medical and Research Center, Qatar

Back to top

Section: Translational Cancer Biology

Cristina Maccalli, MSc., Ph.D., is a Principal Investigator at the laboratory of Immune Biological Therapy, Cancer Program, Research Department of Sidra Medicine, Doha, Qatar. Dr Maccalli obtained in 1990 a master’s degree in Biological Sciences and then, in 1996, a Ph.D. in Applied Genetics at the University of Milan, Italy. She has carried out her post-doctoral research programs at the National Cancer Institute in Milan, Italy and then, at the Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA. From 2003 until mid-2007, she worked as investigator at the Istituto Superiore di Sanita’ Rome, Italy. In 2007, Dr Maccalli joined as Senior Investigator the Unit of Immuno-biotherapy of Melanoma and Solid Tumors at the San Raffaele Foundation Scientific Institute, Milan, Italy. In 2013, she contributed to set up in the context of the Italian Network for Biotherapy of Tumors-(NIBIT) a novel laboratory dedicated to the identification of biomarkers for cancer patients through the design of standardized and validated immune-monitoring assays. In October 2015, Dr Maccalli joined the Research Department at Sidra Medicine.

Her research interest lies in the area of immunology, tumor immunology and immunotherapy, with main focus on the functional and immunological characterization of cancer stem cells and the development of immune cell-based therapy for cancer patients.

Dr Maccalli is the author/co-author of 67 original peer-reviewed publications and 6-chapter books. She was the Chair of the conference ”Engineered Immune Cells in Cancer Immunotherapy: from Discovery to “Off-the-Shelf” Development” held on the 15-17th of February 2019, in Doha Qatar. She serves as member of Biomarker Working Group (Society of Immunotherapy of Cancer, SITC, USA). In 2020, she has been awarded of the SITC- ”Team Science Recognition Award”.

Marcello Maggiolini, PhD, University of Calabria, Italy

Back to top

Section: Translational Signaling and System Biology

Prof Marcello Maggiolini is Full Professor of General Pathology at the Department of Pharmacy, Health and Nutritional Sciences of University of Calabria. 

He earned a medical degree at the University of Padova, thereafter he obtained the title of specialist in Endocrinology at the University of Rome (A. Gemelli Hospital) and the title of specialist in medical genetics at the University of Catania. From 1998 to 1999, he was Visiting Professor at the Department of Cellular Biology, University of Genève.

At the University of Calabria, he held the position of Director of the Pharmaco-Biology Department from 2005 to 2012, Member of the Academic Senate from 2006 to 2012, Chairman of the Board of the Department’s Directors from 2006 to 2012, Member of the Administration's Board from 2013 to 2019, Coordinator of the Degree Course in Medicine and Surgery TD (Digital Technologies) from 2021. He is Member of Italian Society of General Pathology and Translational Medicine. Prof Maggiolini has co-authored more than 180 indexed publications (H-index =52) (Source: Scopus). He is Associate Editor, Editorial Board Member and Reviewer of several international journals. He obtained several grants focusing on the following research interests: i) novel mechanisms involved by estrogen and growth factors signaling in breast cancer progression, ii) microenvironment players triggering cancer development, iii) hypoxia-mediated cancer stimulation, iv) computer modeling and bioinformatics.

Vijay Mahant, PhD, MediLite Diagnostika, Inc., USA

Back to top

Section: Translational Medicines 'Ecosystem'

Vijay Mahant (MS, Ph.D.) is the CEO and a director at Renova Therapeutics. Renova is a genetic medicine company focused on heart failure and type 2 diabetes. He is a visionary and a pioneer scientist in the healthcare industry with entrepreneurial qualities that span more than three decades in genetic diseases, infectious diseases, and precision medicine (oncology, cardiovascular diseases, neuropsychiatry & pain management). 

Vijay Mahant’s focus over the last decade has been on therapeutics. Vijay Mahant brings in vast experience and wealth of knowledge including skills ranging from research and development, including numerous FDA cleared & CE Marked products, fundraising, IPOs, acquisitions, licensing with conglomerates and major institutes, manufacturing, clinical trials and intellectual property management. He has held senior positions at Nicholas Institute/ Quest, and executive positions at Qualigen, and AGI. He is a former founder and/or co-founder of diagnostic companies including MediLite Diagnostika and a former executive at oncology companies. He serves on the SAB/MAB of young oncology companies such as Trutino Biosciences and an oncology hospital. Vijay Mahant has authored and/or co-authored publications in peer-reviewed science and/or medical journals and contributed chapters in books. He has 32 issued international patents in healthcare.

Nehal Mehta, MD, National Heart, Lung and Blood Institute, USA

Section: Cardiovascular, Metabolic and Lipoprotein Translation

Dr Nehal Mehta is a Professor of Medicine at the George Washington University School of Medicine, and an adjunct Associate Professor at the University of Pennsylvania where he serves as the Director of Inflammatory Risk within Cardiovascular Medicine. He is an expert in general cardiology, lipidology, and cardiovascular imaging. Dr Mehta trained at the Hospital of the University of Pennsylvania in Internal Medicine and Cardiovascular Diseases where he also completed a Master’s degree in biostatistics and a post-doctoral program in human translational studies of lipoprotein  pathways. His group was the first to demonstrate the presence of dysfunctional HDL in psoriasis, and Dr Mehta subsequently moved to the National Institutes of Health as the Inaugural recipient of the Lasker Clinical Scholar Award where he served as Section Chief of Inflammation and Cardiometabolic Diseases at the NHLBI. 

He was Director of Cardiovascular Imaging at the NHLBI, and the founding Director and Principal Investigator of the largest cohort study studying psoriasis and cardiometabolic diseases. During that time, he also completed several randomized trials in humans on the impact of biologic therapy on vascular diseases. In 2018, he was awarded an NIH Director's Award for demonstrating that high-risk coronary plaque in humans was improved following treatment of their inflammatory disease, opening up a new path to mitigating risk in populations with chronic inflammation. Dr Mehta has chaired multiple working groups and guideline groups to establish a standard of care for cardiovascular risk reduction in patients with chronic inflammation. 

Dr Mehta was inducted into the American Society of Clinical Investigation in 2018 and received two lifetime achievement awards for his work in cardiovascular risk reduction in inflammation in 2020 (International Federation of Psoriasis and Psoriatic Arthritis) and 2023 (National Psoriasis Foundation). He serves as the cardiovascular editor for the Journal of Translational Medicine, as a board member of the ASPC and is active within the American Heart Association and American College of Physicians as a Fellow and educator.

Sabrina Molinaro, Section Editor

Back to top

Section: Computational Modelling and Epidemiology

Dr Sabrina Molinaro is the Research Director in Epidemiology at Institute of Clinical Physiology, National Research Council (CNR-IFC). The crucial element of her research is to make different disciplines dialogue and to allow the integration of different skills and heterogeneous data. One of the main threads is to draw as much knowledge as possible from existing information. With this aim, since 2010 she has been leading a research group of 25 people (psychologists, biologists, statisticians, economists, jurists, mathematicians, sociologist, archeologists) coordinating both scientific activities and raising funds to complete them. She also deals with conducting studies and disseminating them.

Her main research focuses on 3 main areas: (1) population studies to allow monitoring of health risk behaviors in hidden populations, (2) development of analysis models for public health system and precision medicine, and (3) evaluation of health policies through innovative econometric models.

Gianni Monaco, PhD, University of Freiburg, Germany

Back to top

Section: Network Medicines

Gianni Monaco, PhD, is a Principal Scientist at Sonata Therapeutics, and he is responsible for planning, performing and coordinating scientific projects aimed at evaluating targets to cure cancer and other diseases. His contributions to date demonstrates exceptional knowledge in various aspects of network modeling, computational biology, cancer biology and gene therapy. 

Gianni obtained his PhD in Life Sciences from the University of Liverpool in a joint program with the agency for Science, Technology and Research (A*STAR) in Singapore. In 2018, he was a researcher at the University Hospital of Basel in Switzerland. In 2021, he was awarded a prestigious Marie Curie Fellowship by the European Commission to conduct research at the Medical Center of the University of Freiburg in Germany.

Over the years, he developed strong organizational, computational and analytical skills within the various scientific organizations and he has co-authored fundamental research in the fields of flow cytometry, evolutionary biology and immune-oncology.

Melissa Myint, PhD, Sonata Therapeutics, USA

Back to top

Section: Cell Death and Senescence

Melissa Myint is Vice President, Head of Exploratory Biology at Sonata Therapeutics, where she leads a team of scientists in early discovery efforts to unravel the complex multi-cellular networks involved in driving fibrosis. Their goal is to develop meaningful network medicines for the treatment of fibrotic disease across diverse populations and manifestations of the disease. 
Previously, Melissa served as Senior Director of Research and Translational Sciences at Mana Therapeutics, where she oversaw all internal assay development activities and managed preclinical study execution across multiple CROs to deliver on two IND submissions for Mana's allogeneic T cell program. Prior to Mana, she held multiple roles of increasing responsibility at SQZ Biotechnologies, where she established preclinical proof-of-concept for two products in SQZ’s immuno-oncology pipeline.
Melissa received her B.S. in Chemical Engineering from Tufts University and her Ph.D. in Chemical Engineering from the University of Pennsylvania.

Salvatore Nesci, PhD, University of Bologna, Italy

Back to top

Section: Cellular Metabolism Therapy

Salvatore Nesci, PhD, is Associate Professor of Biochemistry at the Department of Veterinary Medical Sciences of University of Bologna.

In 2004, he was awarded a Bachelor’s in Biology at the University of Calabria and two years later a Master’s in Biology at the same university. In 2009 he obtained his PhD degree in Biochemistry at the University of Bologna. Afterwards, he spent two years as post-doc fellow before winning the position of researcher. He completed his tenure track by spending a few periods abroad in the laboratories of Dr Cinta Porte (Barcelona, Spain) and Prof Mike Murphy (Cambridge, UK). Since 2020 he has covered the role of Associate Professor in Biochemistry and group leader of the Mitochondrial Biochemistry lab at the Department of Veterinary Medical Sciences of the University of Bologna.

He is Associate Editor, Editorial Board Member and Reviewer of several international journals.

His research is focused on the molecular mechanisms involved in the biological transduction of energy in mitochondria, cell metabolism analysis, and studies of enzymatic kinetic approaches on structure-activity relationship (SAR) and function.

Monica C Panelli, PhD, University of Pittsburgh, USA

Back to top

Section: Illnesses of Unknown Etiology

Dr Monica C Panelli is a Senior Editor and Section Editor (Illnesses of Unknown Etiology) of the Journal of Translational Medicine (2002 to present). Dr Panelli transitioned from academia to Amgen Medical Information-Oncology therapeutic area with responsibility for marketed and pipeline oncology products (2010-2013). As a Tumor Immunologist, Dr Panelli conducted clinical/ translational cancer research focused on melanoma and monitored clinical trials at NIH/NCI and academia/University of Pittsburgh Cancer Institute (UPCI). She was a visiting Associate Professor at University of Pittsburg Cancer Institute (UPCI), Pittsburgh, Pennsylvania USA; Director of Immunogenomics an Immunoproteomics UPCI Core Services; and Director of Clinical Genomics/Proteomics and Tissue Banking, UPCI Melanoma and Skin Cancer Program (2007-2009). Dr Panelli was a Staff Scientist and Supervisor Proteomic Unit 2002-2006 at National Institutes of Health (NIH), Clinical Center (CC) Department of Transfusion Medicine Bethesda Maryland, USA.

Dr Panelli is a reviewer for numerous scientific journals and has granted proposals for domestic (NSF) and international (SFI and AIRC) foundations. She has served in intramural (NIH and UPCI), extramural (ECOG, Industry) and international (International Melanoma Working Group-IMWG) advisory committees for cancer therapeutics. Dr Panelli is an ASCO and SITC active member.

Maria Jose Polanco Mora, PhD, Universidad San Pablo CEU, Spain

Back to top

Section: Neuroscience

María José Polanco Mora, PhD, is Professor of Pharmacology and Toxicology (University San Pablo CEU, Madrid, Spain). Dr Polanco obtained her Ph.D. degree in Neuropharmacology in 2011 (University San Pablo CEU, Madrid, Spain), was a visiting researcher in the University of Glasgow (Glasgow, Scotland) and completed her post-doctoral training in the Italian Institute of Technology (IIT, Genova, Italy) and in the Center of Integrative Biology (CIBIO, University of Trento, Italy) in 2017. She is a member of the research group NEUROFAN (Neuropharmacology of addiction and neurodegenerative diseases). Her current research activities center on the molecular mechanisms underlying motor neuron diseases, such as Kennedy´s disease and amyotrophic lateral sclerosis (ALS).

Previously, she served as Associate Editor for the Journal of Translational Medicine. She is a member of Neuroscience expert panel for Marie Sklodowska-Curie Actions (European Commission). She is the president of the Commission of the Research Ethics Committee (University San Pablo CEU).

Jessica Roelands, PhD, Leiden University Medical Center, Netherlands

Back to top

Section: Cancer Microenvironment

Dr Jessica Roelands is a computational biologist and principal investigator at the Department of Pathology at Leiden University Medical Center (LUMC) in the Netherlands. Her research focuses on unravelling the complex dynamics of the tumour immune-microenvironment to improve cancer prevention and treatment.

During her PhD at Sidra Medicine in Doha, Qatar, she played a crucial role in initiating a collaborative project between LUMC and Sidra. Dr Roelands conducted extensive profiling of a large cohort of colon cancer patients, integrating genomic, immunological, and microbiome sequencing data to elucidate the impact of immune-bacteria interactions on patient prognosis. After four years at Sidra Medicine, she joined the Cancer Immunogenomics group at LUMC for her post-doctoral research. Here, she advanced her work by developing innovative approaches to study colorectal cancer onset and progression, employing spatial transcriptomics, imaging mass cytometry, and multi-plex immunodetection. Currently, Dr Roelands focuses on understanding the interplay between tumor cells, the immune system, and bacteria during colorectal cancer tumorigenesis.

Dr Roelands co-edits this section with Dr Bedognetti. 

Mary Salvatore, MD MBA, Columbia University, USA

Back to top

Section: Fibrosis

Mary Salvatore, MD MBA, is an associate professor of radiology at Columbia University Irving Medical Center in New York City. She is an expert in thoracic radiology with focus on lung fibrosis and other interstitial lung diseases. She has a passion for research and education with many publications in renowned medical journals. Her research focuses on the improvement of early diagnosis of idiopathic pulmonary fibrosis and other diseases of the thorax using CT scan. She believes that inflammation, fibrosis, and cancer are interrelated and cause most diseases in the body.

Jingxuan Shan, PhD, Weill Cornell Medicial College in Qatar, Qatar

Back to top

Section: Personalized Medicine

Jingxuan Shan, PhD, is a senior research scientist in Genetic Intelligence lab in Weill Cornell Medicine-Qatar. Dr Shan obtained his MSc and PhD in Genetics from Fudan University (Shanghai). He completed his postdoctoral training the field of translational study of breast/prostate cancer in Weill Cornell Medicine-Qatar after he left GenenDesign (Shanghai), which is dedicated to building cancer models for personalized cancer drug discovery and where he was a founding member. 

His research interests include identification of genetic causes of rare disease, investigation of genetic and lifestyle risk factors for cancer and obesity and the development of therapeutics for these two diseases. 

Laura Soldati, PhD, University of Milan, Italy

Back to top

Section: Nutrition & Metabolism

Laura Soldati is contract Professor in Applied and Technical Dietary Sciences at. Specialization Schools in Nutrition Sciences and in Nephrology at the University of Milan, Italy, with Suitability as Associate Professor (2017-23). She was Member of the Council of the PhD Program in Molecular and Translational Medicine (2000-2019). Dr Soldati was also a Member of the Animal Welfare Organization (OPBA) (2014-2016), Consultant at the Sidra Medical and Research Center, Doha, Qatar (2015) and a Member of the Academic Senate, representative of Medical Sciences (2016-2018).

Mia Stanic, PhD, University of Toronto, Canada

Section: Cancer Metabolism

Mia Stanic, PhD is a Postdoctoral Research Associate at the University of Toronto. She is an expert in the area of molecular biology of viruses and cancers, as well as human genome organization and immunology and advanced analytical techniques. She obtained her Master Degree at the Science Faculty at Sarajevo University in the area of genome biology and population genetics. She obtained her PhD Degree at Heidelberg University in the area of human genome biology and HIV-1 molecular genetics. 

Currently she is working at the University of Toronto studying the backgrounds of aging, DNA repair mechanisms and cancer development in humans. She is the author of multiple original research publications with significant contributions to the DNA repair field. 

Mia has been engaged with Journal of Translational Medicine since 2021 where she contributed to the conceptual and formal editing of numerous scientific manuscripts focused on human disease, cancer and metabolism, clinical science and research. 

Sarah Warren, PhD, Kite Pharma, USA

Back to top

Section: Molecular Pathology

Sarah Warren, Ph.D. joined Gilead Sciences in 2022 and currently is a Senior Director of Corporate Development leading cell therapy search and evaluation. In this role, she is responsible for identifying external advances in cell therapy that complement and accelerate the internal research and development programs to accelerate the pace at which cell therapies become available to patients. Prior to joining Gilead, she built and led the Translational Science program at NanoString Technologies that applied multiplexed, molecular profiling technologies to research and diagnostic projects spanning oncology, immunology, and beyond. She was also a founder and Director of Research at Oncofactor Corp, a biotechnology company focused on novel immune checkpoints. 

She is active in the immuno-oncology research community, having published more than 60 manuscripts and currently serves on the Board of Directors for the Society of Immunotherapy for Cancer and is a founding mentor for the Creative Destruction Labs Computational Health stream. She has a PhD in immunology from the University of Washington and performed her graduate work at the Institute for Systems Biology profiling and engineering immune responses to prokaryotic pathogens. She has been an editor with Journal of Translational Medicine since 2018, first as an Associate Editor for the Immunobiology and Immunotherapy section and now Section Editor for Molecular Pathology. 

Liang Zhong, PhD, Paraza Pharma Inc, Canada

Section: Cancer Metabolism

Dr Liang Zhong is the editor for the Cancer Metabolism section of the Journal of Translational Medicine (2023 to present). Dr. Zhong obtained his PhD in Cell and Molecular Biology from Laval University, before working at Harvard Medical School as a research fellow. His research covers oncology, stem cell, blood diseases, and drug development. Dr. Zhong received 17 NIH grants for his research. He is currently working as a research scientist at Paraza Pharma and serves on the editorial board of nine journals and is a valued speaker at Cold Spring Harbor Laboratory.

Annual Journal Metrics